Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117691 | 0.85 | NOS2 (0.45) | NOS2NOS3TAAR1HTR1ACYP2A6 | |
| Hydrochloric Acid SCHEMBL11412747 | 0.80 | NOS2 (0.37) | NOS2NOS3TAAR1HTR1ACYP2A6 | |
| SCHEMBL25652166 | 0.80 | PDE3B (0.39) | NOS2NOS3TAAR1HTR1APDE3B | |
| SCHEMBL25652149 | 0.80 | KDM4E (0.40) | NOS2NOS3TAAR1HTR1ACYP2A6 | |
| SCHEMBL11412750 | 0.79 | NOS2 (0.38) | NOS2NOS3TAAR1HTR1A | |
| SCHEMBL31214431 | 0.79 | MAOA (0.36) | — | |
| SCHEMBL5009720 | 0.77 | NOS2 (0.45) | NOS2NOS3TAAR1CYP2A6 | |
| Hydrochloric Acid SCHEMBL3899633 | 0.75 | NOS2 (0.44) | NOS2NOS3TAAR1CYP2A6 | |
| SCHEMBL31150927 | 0.75 | LMNA (0.34) | NOS2NOS3TAAR1CYP2A6 | |
| SCHEMBL21850486 | 0.74 | NOS2 (0.37) | NOS2NOS3TAAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | NICOYA THERAPEUTICS (SHANGHAI) CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183221-A1 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | XDH, CYP11B2, DPYD | NOS2 1505/4885NOS3 1523/4885TAAR1 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.